Abiraterone Acetate NDC 82293-002

NDC codes

FDA NDC Directory

Product NDC (as listed)82293-002Labeler and product segments. Claims need a package NDC.

Product NDC at billing width82293-0002Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
82293-002-10	82293000210	60 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (82293-002-10)Marketed from Jan 5, 2022

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Abiraterone Acetate
Generic name (nonproprietary): abiraterone acetate
Active ingredients: Abiraterone acetate — 500 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Novugen Pharma (USA) LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 215947
Marketing start: Jan 5, 2022
Listing expires: Dec 31, 2027
Other FDA classes: Cytochrome P450 17A1 Inhibitors (Mechanism)Cytochrome P450 2C8 Inhibitors (Mechanism)Cytochrome P450 2D6 Inhibitors (Mechanism)
Identifiers: Product ID 82293-002_47d0b34a-b255-d3a9-e063-6294a90aadb6SPL ID 47d0b34a-b255-d3a9-e063-6294a90aadb6SPL set ID f308b463-27e4-422a-95a2-ecbbf95eee20RxCUI 1100075, 1918042UNII EM5OCB9YJ6UPC 0382293002108, 0382293001101
Pharmacologic class: Cytochrome P450 17A1 Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N482293000210 followed by a unit qualifier and the quantity

Package 82293-0002-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 7, 2026.

Indications (excerpt from the label)

Abiraterone acetate tablets are indicated in combination with prednisone for the treatment of patients with: Metastatic castration-resistant prostate cancer (CRPC) Metastatic high-risk castration-sensitive prostate cancer (CSPC) Abiraterone acetate is a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with: metastatic castration-resistant prostate cancer (CRPC). ( 1 ) metastatic high-risk castration-sensitive prostate cancer (CSPC). ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 215947

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 215947
Product	Strength	Form · route	Labeler	Product NDC
Abiraterone Acetate	Abiraterone acetate 250 mg/1	Tablet, Film coatedOral	Novugen Pharma (USA) LLC	82293-001